Alyea, Edwin P <br/><br/>
Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.  [electronic resource] 

 -  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation  Aug 2008 
 - 920-6 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1523-6536 
<br/><br/><label>Standard No.: </label>10.1016/j.bbmt.2008.05.024  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Busulfan--therapeutic use<br/>Female<br/>Graft Survival<br/>Graft vs Host Disease--drug therapy<br/>Hematologic Neoplasms--complications<br/>Histocompatibility Testing<br/>Humans<br/>Immunosuppressive Agents--administration & dosage<br/>Male<br/>Methotrexate--administration & dosage<br/>Middle Aged<br/>Peripheral Blood Stem Cell Transplantation--adverse effects<br/>Premedication<br/>Sirolimus--administration & dosage<br/>Tacrolimus--administration & dosage<br/>Tissue Donors<br/>Transplantation Conditioning--methods<br/>Transplantation, Homologous<br/>Vidarabine--analogs & derivatives